[Percutaneous coronary intervention in stable coronary artery disease].

Percutaneous coronary intervention is a well-established symptomatic therapy of stable coronary artery disease. Using a literature search with special emphasis on the newly-published FAME 2 trial data, the author wanted to explore why percutaneous coronary intervention fails to reduce mortality and myocardial infarction in stable coronary artery disease, as opposed to surgical revascularisation. In the FAME 2 trial, fractional flow reserve-guided percutaneous coronary intervention with second generation drug eluting stents showed a significant reduction in the primary composite endpoint of 2-year mortality, myocardial infarction and unplanned hospitalization with urgent revascularisation as compared to medical therapy alone. In addition, landmark analysis showed that after 8 days, mortality and myocardial infarction were significantly reduced. The author concludes that percutaneous coronary intervention involving fractional flow reserve guidance and modern stents offers symptomatic, as well as prognostic benefit.
AuthorsZsolt Piróth
JournalOrvosi hetilap (Orv Hetil) Vol. 155 Issue 49 Pg. 1952-9 (Dec 07 2014) ISSN: 0030-6002 [Print] Hungary
Vernacular TitlePercutan coronariaintervenció stabil coronariabetegségben.
PMID25434515 (Publication Type: English Abstract, Journal Article, Review)
  • Coronary Artery Disease (mortality, surgery)
  • Fractional Flow Reserve, Myocardial
  • Humans
  • Percutaneous Coronary Intervention (methods)
  • Randomized Controlled Trials as Topic
  • Stents
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: